Diamonds and Dogs


Synnex (SNX) jumping 10%. The Silicon Valley contract-manufacturing company handily beat earnings and revenue expectations this morning while also raising their quarterly dividend. Synnex reported third-quarter profit of $58.7 million, or $1.47 a share, on sales of $3.67 billion; after adjustments for acquisition-related expenses and other factors, the company claimed earnings of $1.73 a share. Synnex's profit easily topped analysts' average expectation of $1.56 a share. The dividend was hiked 25%. Who knew there was manufacturing work in Silicon Valley?

Ligand Pharma (LGND) taking a hit down 12% due to lost royalties. Amgen's drug, Kyprolis use for multiple myeloma, a cancer formed by malignant plasma cells, failed in a Phase 3 study today. Ligand Pharmaceuticals receives royalties from sales of the multiple myeloma drug. One analyst at Roth Capital trimmed Ligand's price target, but don't worry shareholders, your CEO was able to sell 3000 shares last week at much higher prices. Doesn't sound fair.


Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.